2027 Pershing Square Sohn Cancer Prize
2027 Pershing Square Sohn Cancer Prize supports early-career scientists pursuing bold, high-risk cancer research to advance understanding, diagnosis, prevention, or treatment of cancer.
Browse similar grants
Funder: Pershing Square Philanthropies
Due Dates: October 26, 2026, 5:00 p.m. ET (LOI) | Late February 2027 (Finalist notification) | April 13–14, 2027 (Finalist review) | Late April 2027 (Winner notification) | June 14, 2027 (Award dinner) | July 1, 2027 (Project start)
Funding Amounts: $750,000 per winner over three years ($250,000 annually, including indirect costs)
Summary: Supports early-career scientists pursuing scientifically sound, high-risk cancer research with potential to advance understanding, diagnosis, prevention, or treatment.
Key Information: Applicants must have two to six years of independent laboratory experience by July 2027.
Description
The Pershing Square Sohn Cancer Prize supports early-career scientists pursuing bold research at a stage when traditional funding is lacking. Administered by the Pershing Square Sohn Cancer Research Alliance (PSSCRA), it seeks radically innovative, scientifically sound cancer research grounded in strong rationale and novel methodologies. Projects may span basic research and technological applications, including speculative approaches with potential to produce important findings, shift paradigms, or address unmet needs.
PSSCRA aims to accelerate cures through scientific discovery and collaboration between science and business. Since 2026, the Prize has expanded beyond greater New York City to institutions across the United States. Winners also receive access to cross-institutional partnerships, industry mentors, philanthropic and commercial investors, an annual retreat, and opportunities to present their ideas at conferences and events.
